8-K: XOMA Royalty Reports Strong Q3 2025, Expands Portfolio

XOMA Royalty Corporation announced robust third-quarter and year-to-date 2025 financial results, driven by increased royalty receipts and strategic acquisitions, while highlighting key pipeline advancements.

Summary

• Net income for the third quarter of 2025 was $14.1 million, a significant improvement from a net loss of $17.2 million in the corresponding period of 2024.
• Year-to-date net income for the nine months ended September 30, 2025, was $25.6 million, compared to a net loss of $9.9 million in the same period of 2024.
• Total income and revenues for the third quarter of 2025 increased to $9.4 million from $7.2 million in the third quarter of 2024.
• Year-to-date total income and revenues more than doubled to $38.4 million for the nine months ended September 30, 2025, from $19.8 million in the corresponding period of 2024.
• Cash receipts from partners in the first nine months of 2025 totaled $43.9 million, including $14.3 million from royalties during the third quarter.
• Completed acquisitions of Turnstone Biologics and HilleVax, and announced expected acquisitions of LAVA Therapeutics and Mural Oncology.
• Secured royalty economic interests in two early-stage partnered assets (PF-08046052 and JNJ-89853413) through the announced acquisition of LAVA Therapeutics.
• Key pipeline advancements include Zevra Therapeutics' Marketing Authorization Application (MAA) submission for arimoclomol to the European Medicines Agency (EMA), Rezolute Bio's reconfirmed expectations for December 2025 topline data from its Phase 3 ersodetug trial, and Gossamer Bio's expected February 2026 topline results from its Phase 3 seralutinib trial.
• Cash and cash equivalents stood at $130.6 million as of September 30, 2025, including $85.4 million in restricted cash.

Sentiment

Score: 8

Explanation: The company reported a significant turnaround from net losses to substantial net income, driven by strong revenue growth from existing royalties and strategic acquisitions. Pipeline advancements and a healthy cash balance further contribute to a very positive outlook, despite increased G&A expenses related to deal-making.

Positives

• Achieved a significant turnaround from net losses to net income, reporting $14.1 million in Q3 2025 net income compared to a $17.2 million net loss in Q3 2024, and $25.6 million YTD 2025 net income compared to a $9.9 million YTD 2024 net loss.
• Experienced strong revenue growth, with total income and revenues increasing to $9.4 million in Q3 2025 (from $7.2 million in Q3 2024) and $38.4 million YTD 2025 (from $19.8 million YTD 2024), primarily driven by VABYSMO and OJEMDA.
• Generated substantial cash receipts from partners, totaling $43.9 million in the first nine months of 2025, including $14.3 million from royalties in Q3.
• Expanded its portfolio through strategic acquisitions, completing Turnstone Biologics and HilleVax, and announcing LAVA Therapeutics and Mural Oncology acquisitions, adding new royalty interests.
• Reported positive pipeline progress, including Zevra Therapeutics' MAA submission to EMA for arimoclomol, Rezolute Bio's expected Phase 3 topline data for ersodetug in December 2025, and Gossamer Bio's expected Phase 3 topline results for seralutinib in February 2026.
• Maintained a healthy cash position with $130.6 million in cash and cash equivalents as of September 30, 2025.
• Recorded significant gains on acquisitions, totaling $17.9 million for HilleVax and $1.8 million for Turnstone in Q3 2025.
• Reduced Research and Development (R&D) expenses to $69 thousand in Q3 2025 from $0.8 million in Q3 2024, and to $1.4 million YTD 2025 from $2.0 million YTD 2024.
• Reported no credit losses on purchased receivables in 2025, a significant improvement from $14.0 million in Q3 2024 and $23.0 million YTD 2024.

Negatives

• General and administrative (G&A) expenses increased by $1.7 million in Q3 2025 compared to Q3 2024, primarily due to business development and deal-related costs.
• A significant portion of the cash balance, $85.4 million as of September 30, 2025, is restricted, including $39.9 million reserved for the Mural acquisition and $43.3 million related to the assumed HilleVax lease.

Risks

• Product candidates subject to out-license agreements are still being developed, and licensees may require substantial funds to continue development which may not be available.
• Uncertainty exists regarding whether there will be, or will continue to be, a viable market for the products in which XOMA Royalty has an ownership or royalty interest.
• If the therapeutic product candidates to which XOMA Royalty has a royalty interest do not receive regulatory approval, third-party licensees will not be able to market them.
• Actual results could differ materially from forward-looking statements due to certain risks inherent in the biotechnology industry.

Future Outlook

XOMA Royalty anticipates several clinical readouts over the coming months and quarters that, if positive, can meaningfully shape its business trajectory. The company expects to become a self-sustaining entity from royalties alone over the near term, driven by well-executed commercialization efforts by partners and the emergence of new commercial opportunities from within its portfolio.

Management Comments

• "We continue to execute on innovative ways to increase optionality within our portfolio while maintaining a healthy cash balance and limiting dilution to our shareholders." Owen Hughes, CEO.
• "Growing royalty receipts reflect solid commercial execution on the part of our partners." Owen Hughes, CEO.
• "We look forward to several clinical readouts over the coming months and quarters that, if positive, can meaningfully shape our business trajectory." Owen Hughes, CEO.
• "In the first nine months of 2025, we have received $43.9 million in cash from partners, of which $30.3 million were royalty payments related to commercial sales and $13.6 million in milestone payments and fees." Tom Burns, CFO.
• "In the third quarter, we received $14.3 million in cash from our partners commercial sales." Tom Burns, CFO.
• "With well-executed commercialization efforts by our partners and the emergence of new commercial opportunities from within our portfolio, XOMA Royalty has the potential to become a self-sustaining entity from royalties alone over the near term." Tom Burns, CFO.

Industry Context

XOMA Royalty operates as a biotech royalty aggregator, a specialized niche within the biotechnology and pharmaceutical sectors. This model provides non-dilutive funding to biotech companies by acquiring future economics (royalties and milestones) from their licensed therapeutic candidates. The company's strategy of expanding its portfolio through acquisitions and structuring deals positions it to capitalize on the ongoing need for funding in drug development and the potential for high returns from successful commercialized assets. The focus on early-stage partnered assets and diverse pipeline advancements reflects a broad-based approach to mitigate risk and capture value across various therapeutic areas.

Stakeholder Impact

• Shareholders: Positive impact due to significant net income turnaround, strong revenue growth, strategic acquisitions expanding the portfolio, and potential for future royalty streams. Share repurchases also benefit shareholders.
• Partners: Continued strong commercial execution by partners (e.g., Zevra, Rezolute, Gossamer) is crucial for XOMA's royalty receipts. XOMA's role as a royalty aggregator provides non-dilutive funding to biotech companies.
• Creditors: The company maintains a healthy cash balance and is generating significant cash from operations, which supports its ability to service its debt (Blue Owl Loan).

Next Steps

• Closing of LAVA Therapeutics acquisition.
• Closing of Mural Oncology acquisition (expected in Q4 2025).
• Rezolute to announce topline data from sunRIZE Phase 3 clinical trial for ersodetug in infants and children with congenital HI (December 2025).
• Gossamer Bio to publish topline results from PROSERA Phase 3 study evaluating seralutinib in Functional Class II and III PAH patients (February 2026).
• DARE Bioscience to make DARE to PLAY Sildenafil Cream commercially available via prescription (Q4 2025).
• DARE Bioscience to commence one of two registrational Phase 3 clinical trials investigating Sildenafil Cream, 3.6%, for the treatment of female sexual arousal disorder.
• Ipsen (Day One's partner outside the U.S.) expects to receive EMA regulatory decision on its application to commercialize tovorafenib in the European Union.
• Rezolute expects topline results from upLIFT Phase 3 study of ersodetug for the treatment of tumor HI (second half of 2026).

Key Dates

Recommendation

The company has demonstrated a remarkable financial turnaround, moving from significant net losses to substantial net income in both the quarter and year-to-date periods. This is underpinned by robust growth in royalty and milestone receipts, reflecting successful commercialization efforts by its partners. Strategic acquisitions of Turnstone Biologics and HilleVax, along with announced future acquisitions of LAVA Therapeutics and Mural Oncology, significantly expand the company's portfolio and future revenue potential. A healthy cash position, coupled with a clear pipeline of anticipated clinical readouts, suggests strong future growth catalysts. The management's focus on increasing portfolio optionality while limiting shareholder dilution is a positive sign. The risks mentioned are standard for the biotech industry and appear well-managed given the diversified portfolio. This filing indicates a strong operational and financial trajectory, making it a compelling investment opportunity.

Keywords

Biotechnology, Royalty Aggregator, Financial Results, Q3 2025, XOMA, Acquisitions, Pipeline, Drug Development, Pharmaceutical, Biotech Investments, Revenue, Net Income, Cash Flow, Preferred Stock, Nasdaq